论文部分内容阅读
Roche和GileadSciences公司于6月26日宣布，Roche公司已获得欧洲当局许可，在欧洲上市奥塞米韦(oseltamivirphosphate，Tamiflu)，以用于成人和儿童的流感治疗，及青少年和成人的流感预防。公司于3月已收到CPMP(欧洲专利药品委员会)的推荐许可。本品自1999年获美国许可后已在美
Roche and Gilead Sciences Inc. announced on June 26 that Roche has obtained permission from the European authorities to market oseltamivirphosphate (Tamiflu) in Europe for the treatment of influenza in adults and children, as well as flu prevention in adolescents and adults. The company received the recommended CPMP (European Patent and Drug Commission) approval in March. This product has been in the United States since it was approved by the United States in 1999